<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vmireaviz</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник медицинского института «РЕАВИЗ». Реабилитация, Врач и Здоровье</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-762X</issn><issn pub-type="epub">2782-1579</issn><publisher><publisher-name>РЕАВИЗ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20340/vmi-rvz.2023.1.CLIN.1</article-id><article-id custom-type="elpub" pub-id-type="custom">vmireaviz-541</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Клиническая медицина</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Clinical medicine</subject></subj-group></article-categories><title-group><article-title>Влияние нарушений околосуточных ритмов на клиническую картину заболевания у пациентов с метаболическим синдромом</article-title><trans-title-group xml:lang="en"><trans-title>Impact of circuit rhythms disturbances on the clinical picture of the disease in patients with metabolic syndrome</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1943-6598</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грибанов</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gribanov</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Грибанов Игорь Андреевич, старший преподаватель кафедры медико-биологических дисциплин, </p><p>Самара</p></bio><bio xml:lang="en"><p>Samara</p></bio><email xlink:type="simple">gribanov_doc@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7161-1226</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зарубина</surname><given-names>Е. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Zarubina</surname><given-names>E. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зарубина Елена Григорьевна, доктор медицинских наук, профессор, советник ректора по научной работе, заведующая кафедрой медикобиологических дисциплин, </p><p>Самара</p></bio><bio xml:lang="en"><p>Samara</p></bio><email xlink:type="simple">e-zarubina@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Медицинский университет "Реавиз"<country>Россия</country></aff><aff xml:lang="en">Medical University "Reaviz"<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>13</day><month>11</month><year>2022</year></pub-date><volume>13</volume><issue>1</issue><fpage>44</fpage><lpage>50</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Грибанов И.А., Зарубина Е.Г., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Грибанов И.А., Зарубина Е.Г.</copyright-holder><copyright-holder xml:lang="en">Gribanov I.A., Zarubina E.G.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vestnik.reaviz.ru/jour/article/view/541">https://vestnik.reaviz.ru/jour/article/view/541</self-uri><abstract><p>Целью данного исследования стало изучение влияния темновой депривации различной продолжительности на течение метаболического синдрома (МС).</p><p>Материал и методы исследования. Для реализации поставленной цели нами на основе критериев ВОЗ были отобраны пациенты с метаболическим синдромом и нарушенными циркадными ритмами – всего 102 человека (все мужчины) из числа лиц, постоянно работающих в ночное время, у которых на предварительном этапе было зафиксировано снижение уровня мелатонина. В соответствии с поставленными задачами, 102 пациента работоспособного (молодого возраста по критериям ВОЗ) разделили на три группы по 33, 37 и 32 человека соответственно по критерию «длительность работы в ночное время и длительности анамнеза МС»: 0–5, 5–10 и свыше 10 лет. В первой группе средний возраст составил 30,1 ± 1,4 года, во второй – 36,5 ± 1,5 года, в третьей группе средний возраст не превышал 40,3 ± 0,9 года. В качестве контрольной группы было обследовано 45 пациентов с метаболическим синдромом. Данная группа была сопоставимая с основными группами по фоновой патологии и возрасту и различной длительностью анамнеза метаболического синдрома.</p><sec><title>Результаты</title><p>Результаты. Было установлено, что основной признак метаболического синдрома – абдоминальный тип ожирения (объём талии более 80 см для мужчин) выявлен у 100 % пациентов основных и контрольной групп наблюдения. При этом было установлено, что выраженность абдоминального ожирения сочетается с увеличением индекса массы тела и имеет тенденцию к увеличению у пациентов в основных группах, по сравнению с обследованными из контрольной группы. В контрольной группе у 35,5 % обследованных отмечалась артериальная гипертензия 1–2 степени, и еще у 15,6 % было выявлено повышенное нормальное давление.</p></sec><sec><title>Выводы</title><p>Выводы. У пациентов с метаболическим синдромом на фоне нарушения регуляторных механизмов заболевание протекает тяжелее, чем у пациентов с аналогичной длительностью анамнеза метаболического синдрома, но не имеющих нарушений околосуточных ритмов. Тяжесть течения метаболического синдрома на фоне снижения уровня мелатонина увеличивается по мере длительности нарушения регуляторных механизмов. </p></sec></abstract><trans-abstract xml:lang="en"><p>The purpose of this study was to evaluatey the effect of dark deprivation of various durations on the course of the metabolic syndrome (MS).</p><p>Material and research methods. To achieve this aim, based on WHO criteria, we selected patients with MS and disturbed circadian rhythms – a total of 102 people (all men) from among people who constantly work at night, in whom a decrease in melatonin levels was recorded at a preliminary stage. In accordance with the tasks set, 102 patients (all men) of working age (young age according to WHO criteria) were divided into three groups of 33, 37 and 32 people, respectively, according to the criterion "duration of work at night and duration of history of MS": 0–5, 5–10 and over 10 years. In the first group, the mean age was 30.1 ± 1.4 years; in the second group, the mean age was 36.5 ± 1.5 years; in the third group, the mean age did not exceed 40.3 ± 0.9 years. As a control group, 45 patients with MS were examined, comparable with the main groups in terms of background pathology and age and different duration of MS history.</p><sec><title>Results</title><p>Results. It was found that the main symptom of MS - abdominal type of obesity (waist circumference more than 80 cm for men) was detected in 100% of patients of the main and control groups of observation. At the same time, it was found that the severity of abdominal obesity is combined with an increase in body mass index (BMI) and tends to increase in patients in the main groups, compared with patients from the control group. In the control group, 35.5% of the examined patients had grade 1-2 hypertension, and another 15.6% had elevated normal blood pressure.</p></sec><sec><title>Conclusions</title><p>Conclusions: In patients with MS, against the background of violations of regulatory mechanisms, the disease is more severe than in patients with a similar history of MS, but without violations of circadian rhythms. The severity of the course of MS against the background of a decrease in the level of melatonin increases with the duration of the violation of regulatory mechanisms. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>метаболический синдром</kwd><kwd>мелатонин</kwd><kwd>артериальное давление</kwd></kwd-group><kwd-group xml:lang="en"><kwd>metabolic syndrome</kwd><kwd>melatonin</kwd><kwd>blood pressure</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.</mixed-citation><mixed-citation xml:lang="en">1 Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Jellinger PS, Dickey RA, Ganda OP, Mehta AE, Nguyen TT, Rodbard HW, Seibel JA, Shepherd MD, Smith DA; AACE Lipid Guidelines Committee. The American Association of Clinical Endocrinologists. AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract. 2000 Mar-Apr;6(2):162–213.</mixed-citation><mixed-citation xml:lang="en">2 Jellinger PS, Dickey RA, Ganda OP, Mehta AE, Nguyen TT, Rodbard HW, Seibel JA, Shepherd MD, Smith DA; AACE Lipid Guidelines Committee. The American Association of Clinical Endocrinologists. AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract. 2000 Mar-Apr;6(2):162–213.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007 Jan 30;49(4):403–14. https://doi.org/10.1016/j.jacc.2006.09.032. Epub 2007 Jan 12. PMID: 17258085.</mixed-citation><mixed-citation xml:lang="en">3 Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007 Jan 30;49(4):403–14. https://doi.org/10.1016/j.jacc.2006.09.032. Epub 2007 Jan 12. PMID: 17258085.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Boehm BO, Claudi-Boehm S. The metabolic syndrome. Scand J Clin Lab Invest Suppl. 2005;240:3–13. https://doi.org/10.1080/00365510500236044. PMID: 16112954.</mixed-citation><mixed-citation xml:lang="en">4 Boehm BO, Claudi-Boehm S. The metabolic syndrome. Scand J Clin Lab Invest Suppl. 2005;240:3–13. https://doi.org/10.1080/00365510500236044. PMID: 16112954.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017 May;183:57–70. https://doi.org/10.1016/j.trsl.2017.01.001. Epub 2017 Jan 9. PMID: 28130064; PMCID: PMC5393930.</mixed-citation><mixed-citation xml:lang="en">5 Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017 May;183:57–70. https://doi.org/10.1016/j.trsl.2017.01.001. Epub 2017 Jan 9. PMID: 28130064; PMCID: PMC5393930.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Park SK, Jung JY, Oh CM, Choi JM, Kim MH, Ha E, Kim Y, Ryoo JH. Components of metabolic syndrome and their relation to the risk of incident cerebral infarction. Endocr J. 2021 Mar 28;68(3):253–259. https://doi.org/10.1507/endocrj.EJ20-0486. Epub 2020 Oct 10. PMID: 33041272.</mixed-citation><mixed-citation xml:lang="en">6 Park SK, Jung JY, Oh CM, Choi JM, Kim MH, Ha E, Kim Y, Ryoo JH. Components of metabolic syndrome and their relation to the risk of incident cerebral infarction. Endocr J. 2021 Mar 28;68(3):253–259. https://doi.org/10.1507/endocrj.EJ20-0486. Epub 2020 Oct 10. PMID: 33041272.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):629–36. https://doi.org/10.1161/ATVBAHA.107.151092. Epub 2008 Jan 3. PMID: 18174459.</mixed-citation><mixed-citation xml:lang="en">7 Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):629–36. https://doi.org/10.1161/ATVBAHA.107.151092. Epub 2008 Jan 3. PMID: 18174459.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018 Feb 26;20(2):12. https://doi.org/10.1007/s11906-018-0812-z. PMID: 29480368; PMCID: PMC5866840.</mixed-citation><mixed-citation xml:lang="en">8 Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018 Feb 26;20(2):12. https://doi.org/10.1007/s11906-018-0812-z. PMID: 29480368; PMCID: PMC5866840.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17;364(9438):937–52. https://doi.org/10.1016/S0140-6736(04)17018-9. PMID: 15364185.</mixed-citation><mixed-citation xml:lang="en">9 Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17;364(9438):937–52. https://doi.org/10.1016/S0140-6736(04)17018-9. PMID: 15364185.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Poyrazoglu S, Bas F, Darendeliler F. Metabolic syndrome in young people. Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):56–63. https://doi.org/10.1097/01.med.0000436414.90240.2c. PMID: 24247648.</mixed-citation><mixed-citation xml:lang="en">10 Poyrazoglu S, Bas F, Darendeliler F. Metabolic syndrome in young people. Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):56–63. https://doi.org/10.1097/01.med.0000436414.90240.2c. PMID: 24247648.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lemieux I, Després JP. Metabolic Syndrome: Past, Present and Future. Nutrients. 2020 Nov 14;12(11):3501. https://doi.org/10.3390/nu12113501. PMID: 33202550; PMCID: PMC7696383.</mixed-citation><mixed-citation xml:lang="en">11 Lemieux I, Després JP. Metabolic Syndrome: Past, Present and Future. Nutrients. 2020 Nov 14;12(11):3501. https://doi.org/10.3390/nu12113501. PMID: 33202550; PMCID: PMC7696383.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018 Feb 26;20(2):12. https://doi.org/10.1007/s11906-018-0812-z. PMID: 29480368; PMCID: PMC5866840.</mixed-citation><mixed-citation xml:lang="en">12 Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018 Feb 26;20(2):12. https://doi.org/10.1007/s11906-018-0812-z. PMID: 29480368; PMCID: PMC5866840.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenberg K. Shift Work Adversely Affects Mental Health. Am J Nurs. 2020 Mar;120(3):67. https://doi.org/10.1097/01.NAJ.0000656368.67026.9f. PMID: 32079804.</mixed-citation><mixed-citation xml:lang="en">13 Rosenberg K. Shift Work Adversely Affects Mental Health. Am J Nurs. 2020 Mar;120(3):67. https://doi.org/10.1097/01.NAJ.0000656368.67026.9f. PMID: 32079804.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Folkard S. Shift work, safety, and aging. Chronobiol Int. 2008 Apr;25(2):183–98. https://doi.org/10.1080/07420520802106694. PMID: 18484360.</mixed-citation><mixed-citation xml:lang="en">14 Folkard S. Shift work, safety, and aging. Chronobiol Int. 2008 Apr;25(2):183–98. https://doi.org/10.1080/07420520802106694. PMID: 18484360.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Arlinghaus A, Bohle P, Iskra-Golec I, Jansen N, Jay S, Rotenberg L. Working Time Society consensus statements: Evidence-based effects of shift work and non-standard working hours on workers, family and community. Ind Health. 2019 Apr 1;57(2):184–200. https://doi.org/10.2486/indhealth.SW-4. Epub 2019 Jan 31. PMID: 30700670; PMCID: PMC6449634.</mixed-citation><mixed-citation xml:lang="en">15 Arlinghaus A, Bohle P, Iskra-Golec I, Jansen N, Jay S, Rotenberg L. Working Time Society consensus statements: Evidence-based effects of shift work and non-standard working hours on workers, family and community. Ind Health. 2019 Apr 1;57(2):184–200. https://doi.org/10.2486/indhealth.SW-4. Epub 2019 Jan 31. PMID: 30700670; PMCID: PMC6449634.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Isbit J. Preventing diseases of civilization. J Pediatr Surg. 2018 Jun;53(6):1261. https://doi.org/10.1016/j.jpedsurg.2018.02.099. Epub 2018 Apr 9. PMID: 29729822.</mixed-citation><mixed-citation xml:lang="en">16 Isbit J. Preventing diseases of civilization. J Pediatr Surg. 2018 Jun;53(6):1261. https://doi.org/10.1016/j.jpedsurg.2018.02.099. Epub 2018 Apr 9. PMID: 29729822.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kopp W. How Western Diet And Lifestyle Drive The Pandemic Of Obesity And Civilization Diseases. Diabetes Metab Syndr Obes. 2019 Oct 24;12:2221–2236. https://doi.org/10.2147/DMSO.S216791. PMID: 31695465; PMCID: PMC6817492.</mixed-citation><mixed-citation xml:lang="en">17 Kopp W. How Western Diet And Lifestyle Drive The Pandemic Of Obesity And Civilization Diseases. Diabetes Metab Syndr Obes. 2019 Oct 24;12:2221–2236. https://doi.org/10.2147/DMSO.S216791. PMID: 31695465; PMCID: PMC6817492.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
